Bristol’s CAR-T Strategy Comes Into Focus With Two Near-Term Filings
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
You may also be interested in...
Research and early development head Rupert Vessey, who had a similar role at Celgene, told Scrip that integration of the company’s pipeline into Bristol is nearly complete with few overlapping programs.
The company believes the PD-1 inhibitor’s recent declines will be reversed through new indications, providing revenue growth along with other new products by the time Revlimid faces generics in 2022.
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.